首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   7385篇
  免费   591篇
  国内免费   354篇
耳鼻咽喉   63篇
儿科学   65篇
妇产科学   16篇
基础医学   251篇
口腔科学   37篇
临床医学   747篇
内科学   3671篇
皮肤病学   16篇
神经病学   222篇
特种医学   692篇
外国民族医学   1篇
外科学   841篇
综合类   1048篇
预防医学   123篇
眼科学   70篇
药学   241篇
  6篇
中国医学   39篇
肿瘤学   181篇
  2024年   5篇
  2023年   136篇
  2022年   171篇
  2021年   360篇
  2020年   339篇
  2019年   284篇
  2018年   343篇
  2017年   258篇
  2016年   316篇
  2015年   341篇
  2014年   595篇
  2013年   583篇
  2012年   417篇
  2011年   474篇
  2010年   404篇
  2009年   432篇
  2008年   386篇
  2007年   447篇
  2006年   352篇
  2005年   289篇
  2004年   258篇
  2003年   207篇
  2002年   217篇
  2001年   146篇
  2000年   100篇
  1999年   86篇
  1998年   111篇
  1997年   97篇
  1996年   34篇
  1995年   52篇
  1994年   36篇
  1993年   14篇
  1992年   15篇
  1991年   12篇
  1990年   5篇
  1989年   3篇
  1987年   2篇
  1982年   1篇
  1980年   1篇
  1979年   1篇
排序方式: 共有8330条查询结果,搜索用时 656 毫秒
1.
Transplant ureteric stent insertion reduces the incidence of MUCs, but it is not known whether routine PSRGU is needed to detect unmasked MUCs. This study evaluated whether routine PSRGU in the pRTR is a useful tool to identify MUCs before they become clinically apparent. A retrospective analysis was undertaken of the clinical outcomes following elective stent removal from pediatric kidney‐only transplant recipients at two London centers between 2012 and 2016. Our policy was to perform PSRGU either routinely or urgently if there were concerning symptoms or biochemical evidence of renal allograft dysfunction. Elective stent removal was performed in 86% (97 of 113 pRTR), and 75 (77%) of whom had routine PSRGU at a median (IQR) of 6 (2‐8) days after stent removal. There were changes to management in 3 (4%) of pRTR with PSRGU identifying no MUC. Nineteen patients (25%) had urgent PSRGU, most commonly due to renal allograft dysfunction, at a median (IQR) of 5.5 (2.7‐12.3) days after stent removal. Of these, two pRTR required ureteric intervention. For our current practice of removing transplant stents at 4‐6 weeks post‐transplantation, our study has found no evidence to support routine PSRGU after elective stent removal.  相似文献   
2.
3.
Central illustration: cumulative major adverse cardiac events (MACE) and bioresorbable vascular scaffold (BVS) thrombosis rates after 1, 2, 3, 4 and 5 years.
  相似文献   
4.
5.
6.
PurposeTo retrospectively evaluate the safety and effectiveness of the Covera stent graft (SG) for the treatment of dysfunctional or thrombosed arteriovenous grafts (AVGs).Materials and MethodsWithin 29 months (February 2016–August 2018), 79 patients underwent Covera SG placement in the authors’ department for the treatment of dysfunctional AVGs. Data were available for 64 patients who underwent 64 procedures, using 64 devices. Minimum follow-up was 6 months, unless reintervention occurred. Mean follow-up was 277 days (6–923 days). Treatment characteristics were 51 cases with venous-graft anastomosis (VGA) stenosis (79.7%), 13 cases of puncture zone stenosis (20.3%), 14 cases of in SG stenosis (21.9%), 8 cases of pseudoaneurysm treatment (12.5%) (1 treatment area might have had more than 1 characteristic). Thirty-six patients presented with thrombosis (56.2%), and 31 of 64 case were de novo treatment areas (48.4%). Primary outcome measurements were technical success and post-intervention primary patency (PIPP) at 6 months, whereas secondary outcome measurements included factors influencing primary outcome.ResultsTechnical success was 100%. Median PIPP was 336 days, and 73.6% of treatment areas were patent at 6 months. There were no significant differences in terms of PIPP when de novo treatment areas were compared with restenotic areas (519 vs. 320 days, respectively; P = .1); patients who presented with versus those who presented without thrombosis (320 vs. 583 days, respectively; P = .07); puncture zone stenosis or elsewhere (329 vs. 686 days, respectively; P = .52); and VGA stenosis or elsewhere (336 vs. 335 days, respectively; P = .9).ConclusionsUse of the Covera SG for AVG treatment was safe and effective in every type of treatment area presented in this retrospective analysis.  相似文献   
7.
8.
目的 :通过观察实验犬下腔静脉内放置可扩张性内支撑后血管的形态学变化 ,确定支撑的内皮化进程 ,以期为临床减少内支撑阻塞、合理应用抗凝剂提供组织学的依据。  方法 :在 14只杂种犬下腔静脉内放置金属内支撑 ,于术后 1个月起 ,逐月取下腔静脉作光镜和电镜检查。  结果 :术后 1个月左右 ,内支撑基本内皮化 ,5个月完成血管的重构。  结论 :早期抗凝治疗是防止内支撑阻塞的关键 ,首次提出内支撑放置后血管重构的现象  相似文献   
9.
Summary A new modification of microvenous anastomosis, which has increased patency rates while simultaneously decreasing the difficulty of the procedure, is presented in this paper. The primary purpose of this study was to compare the classical and the temporary stent techniques of microvenous anastomosis. Because of problems such as mixing and tangling of strings during insertion and tying of the last four sutures while applying the temporary stent technique, we decided to modify the procedure. The silastic tube was removed through an incision (venotomy), distant from the actual suture line. This modified technique and the other above mentioned techniques were carried out on rat femoral veins. The results indicate that this modification has increased patency rates, shortened the time of anastomosis and facilitated the procedure.  相似文献   
10.
食管支架置入术的临床应用   总被引:4,自引:0,他引:4  
目的探讨食管支架置入术对良、恶性食管狭窄和食管瘘的治疗方法、疗效和并发症的处理。方法对55例不同原因所致良、恶性食管狭窄和食管瘘患者采用食管金属支架置入术。结果食管狭窄的主要症状吞咽困难、呛咳得到改善,近期疗效达100%。出现的并发症主要为疼痛和大便隐血,发生率分别为100%和92.7%,其余依次为胃食管返流、食管再狭窄、支架脱落,经过治疗后得到缓解或消失。结论金属支架置入术是治疗中晚期食管癌、狭窄的有效方法之一,对食管良性狭窄和瘘效果亦好。并发症可以预防,处理后大部分缓解。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号